Day One Biopharmaceuticals, Inc.

NASDAQ•DAWN

CEO: Dr. Jeremy Bender M.B.A., Ph.D.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2021-05-27

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Contact Information

2000 Sierra Point Parkway, Suite 501, Brisbane, CA, 94005, United States

650-484-0899

dayonebio.com

Market Cap

$1.03B

P/E (TTM)

-9.7

19.9

Dividend Yield

52W High

$13.20

52W Low

$5.64

52W Range

58%

Rank53Top 76.1%

2.8

F-Score

Modified Piotroski Analysis

Based on 6-year fundamentals

Weak • 2.8 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2020-2025

Financial Dashboard

Q4 2025 Data

Revenue

$53.72M+0.00%

4-Quarter Trend

EPS

-$0.21+0.00%

4-Quarter Trend

FCF

-$17.65M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Product Revenue Surges Product revenue reached $155.4M, up 171.6% in 2025, driven by successful US commercial launch of OJEMDA.

Operating Loss Significantly Narrows Loss from operations improved $89.5M to $127.8M, primarily due to lower R&D expenses in 2025.

R&D Spend Decreases Research and development expenses decreased $79.6M to $148.1M, reflecting reduced upfront license milestone payments.

Pipeline Expansion Completed Acquisition of Mersana closed January 2026, adding Emi-Le, positioning company for oncology portfolio expansion.

Risk Factors

Continued Net Losses Expected Incurred $107.3M net loss in 2025; expects continued losses indefinitely, making profitability uncertain for foreseeable future.

OJEMDA Commercialization Dependency Near-term revenue highly dependent on successful OJEMDA commercialization; failure materially affects financial condition and stock price.

Clinical Trial Uncertainty Remains Clinical trials are expensive and time-consuming; earlier positive results may not predict later-stage success or regulatory approval.

Reliance on Third-Party Manufacturers Reliance on limited third parties for manufacturing and clinical trials introduces supply chain, quality, and operational risks.

Outlook

Tovorafenib Phase 3 Completion Expect FIREFLY-2 Phase 3 trial enrollment completion in H1 2026 to support full OJEMDA regulatory approval.

Emi-Le Clinical Data Update Plan to present clinical data for Emi-Le (ACC ADC) mid-2026 to support potential rapid development pathway.

DAY301 Program Update Plan to present initial clinical data for DAY301 (PTK7 ADC) in the second half of 2026.

Expand Targeted Oncology Pipeline Continue leveraging BD expertise to identify, acquire, and develop additional high-impact targeted oncology assets.

Peer Comparison

Revenue (TTM)

ARVN

$262.60M

-0.3%

AKBA

$236.19M

+47.5%

VALN

$198.55M

+13.5%

Gross Margin (Latest Quarter)

VIR

672.1%

-54902.1pp

ATXS

100.0%

+0.0pp

GERN

97.3%

-45.2pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
ERAS	$4.37B	-31.3	-33.1%	11.5%
TERN	$3.74B	-40.3	-30.0%	0.3%
OLMA	$1.84B	-13.4	-41.5%	1.3%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

20.4%

Strong Growth

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:May 13, 2026

EPS:-$0.25

Revenue:$54.60M

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data